Status:
TERMINATED
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
Lead Sponsor:
Pfizer
Collaborating Sponsors:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-89 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind stud...
Eligibility Criteria
Inclusion
- Diagnosis of probable Alzheimer disease
- Completed preceding double-blind study (3133L1-2203 US)
- MMSE score \> 9.
Exclusion
- Significant brain MRI abnormalities
- Clinically important psychiatric symptoms
- History of stroke
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00916617
Start Date
June 1 2009
End Date
September 1 2012
Last Update
June 1 2017
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner Alzheimer's Institute
Phoenix, Arizona, United States, 85006
2
Pharmacology Research Institute
Encino, California, United States, 91316
3
Brain Matters Research
Delray Beach, Florida, United States, 33445
4
MD Clinical
Hallandale, Florida, United States, 33009